Mounjaro
‘Unexpected demand’ hits Mounjaro single-use vials
Supplies of single-use vials of diabetes and chronic weight management medication, Mounjaro, are set to be limited over the coming months Pharmaceutical company, Eli Lilly, is forecasting that supplies of …
Petition seeks rethink of GLP-1 RAs compounding ban
Politicians are being urged to reconsider the decision to ban the compounding of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) until supply issues ease Patients are calling for the government’s decision …
Ozempic compounding ban no ‘knee-jerk’ reaction
Department defends recommendation to ban the compounding of semaglutide and tirepatide medications Moves to prohibit pharmacists from compounding replicas of Ozempic (semaglutide) and Mounjaro (tirepatide) were not a “knee-jerk response” …
Compounding ban ‘a significant public health concern’
Government urged to roll back its ban on compounding weight loss drugs Banning the compounding of glucagon-like peptide-2 receptor agonists (GLP-1RAs) medications will limit patient access to the weight loss …
Government acts on compounding concerns
Compounding exemptions for diabetes medications, Ozempic and Mounjaro, will be removed from 1 October, minister reveals Compounding pharmacies will be barred from producing replicas of Ozempic (semaglutide) and Mounjaro (tirazapetide) …
Severe reactions linked to ‘compounded’ Ozempic
Patient violently ill and vomiting blood after taking illegally compounded Ozempic from an online pharmacy Products being sold as compounded Ozempic (semaglutide) and Mounjaro (tirzepatide) are being linked to severe side …
‘King Kong’ drug Mounjaro now in short supply into 2024
Recently launched diabetes med with weight loss hype another victim of ‘larger than expected demand’ Mounjaro, the hotly anticipated competitor to social media-hyped diabetes and de facto weight loss drug …
FDA approves new ‘King Kong’ weight loss drug
Potential blockbuster dubbed Zepbound to join cousin drug Mounjaro on US market Tirzepatide, Eli Lilly’s GIP and GLP-1 agonist, described by media as “the King Kong of drugs”, has been …
The ‘Ozempic effect’ hits worldwide share market
Whether health industry or junk food business, steamroller popularity of weight loss drug shakes up stock prices The huge success of the new wave of GLP-1 (glucagon-like peptide-1) receptor agonist …
World news wrapup: 21 September 2023
Eli Lilly takes action over copy-cat Mounjaro; Pope praises papal pharmacy staff; Pharmacist facing fraudulent export charges US: Pharmaceutical giant, Eli Lilly, is taking legal action against a number of …
Ozempic competitor to launch in spite of PBS knockback
Eli Lilly’s Mounjaro will be on the private scrip market by the end of September Revolutionary new type 2 diabetes drug Mounjaro – which is almost better known for producing …
Ozempic diabetes competitor gets PBS knockback
Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via …